°Ê²¼¡¢¤³¤Î¥Ú¡¼¥¸(°ìßÜÅþŷμÉûºîÍÑÉ÷ðª²òÀÏ)¤Î¥á¥¤¥ó¥³¥ó¥Æ¥ó¥Ä¤Ç¤¹¡£
Åê¹ÆÆü»þ 2025-10-3 12:11 °ìßÜÅþŷμÉûºîÍÑÉ÷ðª²òÀÏ | |
---|---|
¥²¥¹¥È | °ì¡¢¸¦µæÇØ·ÊçÐÌÜŪ¡§²òÀϰìßÜÅþŷμÉûºîÍÑçÐÃËÀ±ä»þé»°ÂÁ´À ºß¸½ÂåÃËÀ·ò¹¯Îΰ衤ËÖµ¯¸ùǽ¾ã㨡ÊErectile Dysfunction, ED¡ËµÚÀÀ¸³è»ýµ×ÎÏÉÔ¡¤À§ÃËÀºÇ¾ï¸«Åªº¤¾ñÇ·°ì¡£º¬Ú¡¡ÔJournal of Sexual Medicine¡ÕÅý·×¡¤Á´µåÌóÍ 3.5 ²¯ÃËÀ¸ºßÉÔÆ±ÄøÅÙŪEDÌäÂê¡¤Â¶ÃæÐ³½§ÃÏÒ¿ÈæÎã¹âã 20%–30%¡ÊKhera, 2020¡Ë¡£ °øº¡¡¤»ÔÌ̾å½Ð¸½µö¿ÃËÀÊÝ·òÉÊ¡¤Â¶Ãæ °ìßÜÅþŷμ±ä»þç±囊 çР°ìßÜÅþŷμÔãÍÛé» °Ê±ä»þçнõËÖÚò̼õÅþïðÃí¡£Á³¼©¡¤°ìßÜÅþŷμÉûºîÍÑ çР°ìßÜÅþŷμÔãÍÛé»É÷ðª ÉÔÍÆ¹ú»ë¡£ËÜʸÕò×ÏîÐÕܳÑÅٿʹԠÃËÀ±ä»þé»ÉûºîÍÑÈæ³Ó¡¤Äó¶¡°ÂÁ´»ÈÍѻذú¡£ Æó¡¢°ìßÜÅþŷμ±ä»þç±囊ÉûºîÍÑçÐ產ÉÊÀ®Ê¬Ê¬ÀÏ °ìßÜÅþŷμ±ä»þç±囊 çР°ìßÜÅþŷμÔãÍÛ黠ŪÀ®Ê¬²Äʬ°ÙÑÀÎà¡§ Å·Á³ÁðËÜÀ®Ê¬ Êñ³ç¼¯ÊÜ¡¢àõ卡¡¢¿Íèõ¡¢°üÍÓ藿¡¢ÛÎÛ¹Åù¡¤Í½õ²þÁ±ÀºÎÏçзì±Õ½Û´Ä¡£ »°¡¢°ìßÜÅþŷμÉûºîÍÑʬÎà¡§ÃËÀ±ä»þé»ÉûºîÍÑÈæ³Ó 1. íËÅÙÉûºîÍѡʾ︫°ìßÜÅþŷμÉûºîÍÑ¡Ë Æ¬ÄË¡¢Æ¬Úô¡¢çÀÉôĬ¹È¡§Ìó 10%–16% PDE5 ÍÞÀ©Ñý»ÈÍѼÔÊó¹ð¡ÊGoldstein, 2018¡Ë¡£ °ßÄ²Æ»È¿Øæ¡§噁¿´¡¢°ßı¡¢¾Ã²½ÉÔÎÉ¡£ íËÈù·ìÔÚÇÈÆ°¡§Éôʬ¿Í²Äǽ½Ð¸½Ã»»Ã·ìÔÚ²¼¹ß¡£ 2. ÃæÅÙÉûºîÍѡʰìßÜÅþŷμ±ä»þç±囊ÉûºîÍÑÊó¹ð¡Ë ¿´Ø©¡¢¿´Î¨²Ã²÷¡§Ìà¶çÐ咖啡°ø°¿¼òÀºÆ±Éþ¡£ »ëë´Ìϸҡ¢¼ªÌÄ¡§Ìó 3% »ÈÍѼÔû»Ã½Ð¸½»ëë´°Û¾ï¡ÊKloner, 2017¡Ë¡£ ²áÅÙÈèÒ©¡§·ìήʬÉÛ²þÚβÄǽ±Æ¶ÁÂç窶¡·ì¡£ 3. Óî½ÅÉûºîÍѡʰìßÜÅþŷμÔãÍÛé»É÷ðª¡Ë ±¢è³»ýåôËÖµ¯¾É¡ÊPriapism¡Ë¡§Ä¶²á 4 ¾®»þ̤´Ë²ò¡¤²Äǽ¤À®±Êµ×À»½ý¡£ ¿´·ì´É»ö·ï¡§¿´¹ÊÄË¡¢¿´Î§ÉÔÀ°¡¤¿Ó»êà̻ࡤÌà¶ÖáÍ¿´çÇɰ¿¹â·ìÔÚ´µ¼Ô¡£ ´Î¿ÕÉéÙ¿¡§Ä¹´ü»ÈÍѲÄǽùá²Ã´Î¿ÕÂå¼ÕÔÚÎÏ¡£ »Í¡¢°ìßÜÅþŷμÉûºîÍÑâ¤À¸µ¡À©²òÀÏ¡§ÃËÀ±ä»þé»ÉûºîÍÑÈæ³Óçзì´ÉºîÍÑ ·ì´ÉºîÍÑ PDE5 ÍÞÀ©ÑýÆ©²áڲĥ·ì´É¡¢ùá²Ã±¢è³·ìή±äĹËÖµ¯¡¤Ã¢²ÄǽƳÃ×Á´¿È·ìÔÚ²¼¹ß¡¤°úµ¯Æ¬Úôçп´Ø©¡£ ¿Àå´·ÏÅýºîÍÑ ÉôʬÁðËÜÀ®Ê¬¡ÊÇ¡°üÍÓ藿´Þ°üÍÓ藿苷¡Ë¶ñÍÃæÜä¿À崻ɷãºîÍÑ¡¤²ÄǽƳÃ×¼ºÌ²°¿¿´Î¨²Ã²÷¡£ é»Êª¸ò¸ßºîÍÑ çо˻À´ÅÌýÎà¹ßÔÚ黯±ÍѲÄǽÃ×Ì¿ÀÄã·ìÔÚ¡¨¼òÀºËòÐòùᶯÉûºîÍÑÉ÷𪡣 ¸Þ¡¢Î×¾²çÐή¹ÔÉÂÕÜÚËÚ¡¡§°ìßÜÅþŷμÔãÍÛé»É÷ðªçÐÃËÀ±ä»þé»ÉûºîÍÑÈæ³Ó ÈþÔ¢ FDA¡Ê2019¡Ë»Ø½Ð¡¤Ä¶²á 45% ÃËÀÀ¸ùǽÊÝ·òÉÊ´Þ̤ɸ¼¨ÑÝÊýé»À®Ê¬¡£ Î×¾²¸¦µæ¡§À¾ÃÏÆáÈó»ÈÍѼÔÃæ¡¤Æ¬ÄË 16%¡¢Ä¬¹È 10%¡¢¾Ã²½ÉÔÎÉ 7%¡ÊGoldstein, 2018¡Ë¡£ ¡ÔEuropean Urology¡Õ¸¦µæðý¼¨¡¤¿´·ì´É¼ÀÉ´µ¼Ô»ÈÍÑ PDE5 ÍÞÀ©Ñý»þ¡¤Óî½Å¿´·ì´É»ö·ïâ¤À¸Î¨ðýÃø¾å¾£¡ÊAndersson, 2016¡Ë¡£ Ç纳ÚËÚ¡ëúÌÀ °ìßÜÅþŷμÉûºîÍÑ çÐÑÝÊýÔãÍÛé»Áê»÷¡¤ÃËÀ±ä»þé»ÉûºîÍÑÈæ³ÓÉԲĹú»ë¡£ Ï»¡¢¹âÉ÷ðªÂ²·²çаìßÜÅþŷμÉûºîÍÑÃí°Õ»ö¹à ¹âÉ÷ðªÂ²·²¡§¿´·ì´É¼ÀÉ¡¢¹â·ìÔÚ¡¢ÅüǢɡ¢ËýÀ´Î¿Õ¼ÀÉ´µ¼Ô¡£ é»Êª¾×ÆÍ¡§¾Ë»ÀóÅÎàé»Êª¡ÊÇ¡¾Ë»À´ÅÌý¡Ë¡¢Éôʬ¹ßÔÚ黡¢¹³ÉÂÆÇé»Êª¡£ ÆÃ¼ì²·²¡§Ï·Ç¯ÃËÀ¡¢ÉûºîÍÑÂѼõÀÄã¼Ô¼ûÆÃÊ̶࿵¡£ ¼·¡¢°ìßÜÅþŷμ±ä»þç±囊°ÂÁ´»ÈÍÑ»ØÆîçÐÔãÍÛé»É÷ðª´ÉÍý ÑýÎ̹µÀ©¡§ÌÞĶÎÌ¡¤ÈòÌÈáȲÃÉÔÆ±ÔãÍÛ產ÉÊ¡£ Àµµ¬¹ØÇãµôÆ»¡§ÅÎ絕ÐÔ¸»ÉÔÌÀ°¿ÐñËÁ產ÉÊ¡£ ÈòÌȼòÀºÆ±Éþ¡§¹ßÄã¿´·ì´ÉÉûºîÍÑÉ÷𪡣 À¸³èÊý¼°´³Í¡§ µ¬Î§±¿Æ°²þÁ±·ì´É×¼ÀçÐâÐ酮¿åÊ¿¡¨ ¶Ñ¹Õ°û¿©¡¢¸º¾¯Ìýç·¿©Êª¡¨ ²ü菸¸Â¼òÂ¥¿Ê·ì´É·ò¹¯¡£ îÐÎÅ»ðëΡ§ËýÀÉÂÃËÀ»ÈÍÑÁ°ØæÐö¿´ÅÅÔ¦çдðÁÃÜý查¡£ Ȭ¡¢·ëÏÀ¡§°ìßÜÅþŷμÉûºîÍÑçÐÃËÀ±ä»þé»ÉûºîÍÑÈæ³ÓåÁ·ë °ìßÜÅþŷμ±ä»þç±囊çаìßÜÅþŷμÔãÍÛ黳ÎÕé¼õÃËÀ»Ô¾ìÀÄ睞¡¤Ã¢ °ìßÜÅþŷμÉûºîÍÑ çРÔãÍÛé»É÷ðª ÉÔÍÆ¹ú»ë¡£ ×ÏíËÈùƬÄË¡¢Æ¬ÚôÅþÓî½Å¿´·ì´É»ö·ï¶Ñ²Äǽâ¤À¸¡¤ÆÃÊÌÀ§´Þ̤ɸ¼¨é»ÊªÀ®Ê¬Åª產ÉÊÉ÷𪹹¹â¡£ÃËÀØæÍýÀ»ÈÍÑÊÝ·òÉÊ¡¤Æ©²áÀ¸³èÊý¼°²þÁ±À¸ùǽ¡¤ÊºßɬÍ×»þ¿ÒµáÕó¶ÈîлշúµÄ¡£ ¶å¡¢ÒÔ¹ÍʸàÛ Goldstein I, et al. Safety and Tolerability of Sildenafil in the Treatment of Erectile Dysfunction. Journal of Sexual Medicine. 2018. Khera M. Epidemiology of Erectile Dysfunction: Global Perspective. Journal of Sexual Medicine. 2020. Kloner RA. Cardiovascular Effects of PDE5 Inhibitors. Circulation. 2017. Andersson DP, et al. Risk of Cardiovascular Events with PDE5 Inhibitors. European Urology. 2016. U. S. Food and Drug Administration (FDA). Tainted Sexual Enhancement Products. Safety Communication, 2019. Áêïð產ÉÊ¿äÁ¦¡§É¬Íø劲  Ä¶µéÒÖÚôõ°¦ÎÏ °Ò¼©¹Ý¿¿ÕéÚò̰Ҽ©½À ùþÔ¢¹ÈËâ°Ò³ÊÙÇ KAMAGRA-100¿å²ÌÌ£¸ý´ÞÊÒ ¶âïÓ͵éçèÎÏãÒÖÚÃÊÒ ¹á¹ÁÏ·ÃæîÐÀµÉÊÚò̠¹¹Â¿產Éʾܾð¿ÊÆþ¹¯ÜÛé»¶É¡§www.kl19.tw24¾®»þµÒÉþline:kl198888 »ðëÎ ±ä¿閱즡§¹Ã¿½À¸µ»µý¹Åàõ卡ÊÒÍ׵ɿµ×ºÍ´ÇÆÀ½ÐÚò̡© |
°Ê²¼¡¢¤³¤Î¥µ¥¤¥È(¤ß¤ó¤Ê¤ÎÁ¥¶¶)¤Î¥æ¡¼¥¶ÍÑ¥á¥Ë¥å¡¼¤È¡¢ÅÐÏ¿¤µ¤ì¤¿Á¥¶¶ Çð »ÔÀî ½¬»ÖÌî ȬÀéÂå ¤Î´ë¶È¤ªÅ¹¾ðÊó¤Î¥«¥Æ¥´¥ê°ìÍ÷¤Ç¤¹¡£
¤³¤Î¥Ú¡¼¥¸¤ÎÀèÆ¬¤ØÌá¤ë